DOCSLIB.ORG

WHO Drug Information Vol. 07, No. 4, 1993

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Drug Information Vol. 07, No. 4, 1993 WHO DRUG INFORMATION VOLUME 7 • NUMBER 4 • 1993 PROPOSED INN LIST 70 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO DRUG INFORMATION WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters. The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken. WHO Drug Information is published 4 times a year and can be ordered from: Distribution and Sales, World Health Organization, 1211 Geneva 27, Switzerland. Annual subscription: Sw. fr. 60.— Airmail rate: Sw.fr. 72.— Price per copy: Sw.fr. 20.— © World Health Organization 1993 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or in toto, application should be made to: Chief, Office of Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Authors alone are responsible for views expressed in signed contributions. The mention of specific companies or of certain manufacturer's products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. ISSN 1010-9609 World Health Organization, Geneva WHO Drug Information Volume 7, 1993: Index A E ACE inhibitors & digoxin, (4) 169 Essential drugs, (4) 190 Acetylsalicylic acid, (4) 185 Estrogens, topical, (4) 175 Aconite alkaloids, (2) 51 Advertising, European Community, (1) 29 F journals, (3) 115 Aerosol drug delivery, (4) 180 Fees, USA, (4) 189 AIDS update, (4) 163 Folic acid and spina bifida, (3) 106 Ampicillin, (1) 38, (4) 172 Food supplements, (1) 25 Antiarrhythmic agents, (3) 116 Antidepressants and suicide, (1) 18 G Antihyperlipidaemic agents, (3) 123 Gamma-hydroxybutyric acid, (1) 25 Antimicrobial susceptibility testing, Gene therapy, (4) 161 guidelines, (2) 68 Glucocorticoids, inhaled, (4) 170 Antimicrobials, streptococci, (2) 60 Group B streptococcal disease, (2) 64 Antiretroviral drugs, recommendations, (3) 124 Gums, water-soluble, (4) 187 Applications, computerized, (1) 29 Artemisinin, malaria, (3) 111 H Artesunate/mefloquine, (1) 7 Haemophilus influenzae vaccine, (1) 9 Atovaquone, Pneumocystis pneumonia, (3) 123 Halofantrine, data sheet, (2) 67 malaria, (2) 49 B Helicobacter pylori, multidrug therapy, (2) 57 Beclometasone dipropionate, (4) 171 Hepatitis A, vaccine, (3) 132 Benzodiazepines, (1) 23 Hepatitis B immune globulin, (3) 131 Beta-blockers, depression, (1) 14 vaccine, (3) 130 Biotechnology, (1) 29 Hepatitis, viral, (3) 128 products, ADRs, (2) 64 HIV, vaccines, (4) 163 Bismuth subsalicylate, (3) 127 drug-induced cutaneous reactions, (2) 54 Blood products, (4) 185 Hospital-acquired infections, susceptibility, (2) 70 Bovine brain gangliosides, (3) 124 Human immunoglobulin, (3) 132 Budesonide, (4) 171 Hypnotics, short-acting, (3) 125 C I Cefalosporins, sickle-cell disease, (3) 121 ICDRA, (3) 97 Ciprofloxacin, (1) 40 Identification codes, tablets and capsules, (3) 126 Clavulanic acid, jaundice, (1) 33 Immune globulins, nosocomial infections, (1) 16 Cold chain, vaccines, (4) 183 Immunoglobulin, human, (3) 132 Compliance, (4) 181 Guillain-Barré syndrome, (3) 110 Computerized new drug applications, (1) 29 Influenza vaccine, (4) 178 Corticosteroids, asthma, (1) 18 Infrared chemical reference spectra, (1) 27 Coumarins, filarial lymphoedema, (4) 177 Interferon beta-1b, multiple sclerosis, (4) 187 International conference of drug regulatory D authorities, (3) 97 Dapsone-pyrimethamine, (3) 101 International guidelines for biomedical Didanosine, (4) 165 research, (1) 42 Diethylstilbestrol, (3) 103 International infrared chemical reference Digoxin and ACE inhibitors, (4) 169 spectra, (1) 27 Drug labelling, (2) 43 Iron deficiency, (1) 4 Drug regulation, developing countries (1) 1 Isoniazid, tuberculosis, (3) 113 Dysentery, (1) 36 Ivermectin, (1) 6 1 WHO Drug Information Volume 7, Index 1993 K,L S Ketorolac, (2) 64 Second malignancies, (4) 182 Labelling, (2) 43 Slimming regimens, herbal, (2) 52 M Sotalol, (2) 65 Sponsored symposia, (1) 26 Malaria vaccination, (2) 45 Sponsorship, (1) 31 halofantrine, (2) 49 Stavudine, (2) 65 Mefloquine/artesunate (1) 7 Streptococci, antimicrobials, (2) 60 Metronidazole, (1) 41 Sulfamethoxazole/trimethoprim, (1) 38 Misoprostol, (3) 126 Sulfasalazine, (2) 66 Model list of essential drugs, (4) 190 Sumatriptan, (2) 66 Mucosal immunity, vaccine, (2) 55 Symposia, sponsored, (1) 26 Multidose vials, (1) 24 Multidrug-resistant tuberculosis, (1) 21 T Multidrug therapy, Helicobacter pylori, (2) 57 Multiple sclerosis, interferon beta-1b, (4) 187 Tablet identification codes, (3) 126 Tacrine, (3) 104, (3) 127 N Thioacetazone, (1) 21 Transmissible pathogens in biologicals, (3) 118 Nalidixic acid, (1) 39 Tretinoin, topical, (4) 188 Neonatal streptoccal infections, (4) 172 Trimethoprim/sulfamethoxazole, cutaneous Nonsteroidal anti-inflammatories, (1) 33 reactions, (2) 54 Nucleoside therapy, AIDS, (4) 164 Tryptophan, (1) 25 O Oral rehydration salts, (1) 37 U Orphan drugs, (1) 29 UN consolidated list of products whose ORS, (1) 37 consumption and/or sale have been banned, withdrawn, severely restricted or not approved P by governments, (1) 1 Paclitaxel, (1) 35 Paroxetine, (2) 64 V Pathogens in biologicals, (3) 118 Vaccine, Haemophilus influenzae, (1) 9 Patient compliance, (4) 181 hepatitis A, (3) 132 rights, (3) 99 hepatitis B, (3) 130 Pertussis vaccine, (1) 11 influenza, (4) 178 Pharmacists in Europe, (2) 79 malaria, (2) 45 Pneumococcal vaccines, (1) 12 mucosal immunity, (2) 55 Poliovirus vaccines, (3) 108 pertussis, (1) 11 Propofol, (3) 127 pneumococcal, (1) 12 Propylene glycol, control, (3) 127 poliovirus, (3) 108 Psychotropics, pregnancy, (1) 23 Vaccines, cold chain, (4) 183 Pyrimethamine-dapsone, (3) 101 HIV, (4) 163 Vials, multidose, (1) 24 Q Vitamin A, deficiency, (1) 5 Quality assurance, blood products, (4) 185 control in developing countries, (3) 134 W Quinolone antibiotics, (2) 65 Water-soluble gums, (4) 187 Women in trials, (4) 189 R Regulation of drugs, (1) 1 Z Research, international guidelines for Zalcitabine, (4) 166 biomedical, (1) 42 Zidovudine, (2) 47, (4) 165 Rifampicin, (1) 21 2 Volume 7, Number 4, 1993 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Regulatory Matters Gene therapy: the regulatory challenge 161 Acetylsalicylic acid and the heart 185 Blood products and quality assurance 185 Update on AIDS Water-soluble gums: dangers of oesophageal obstruction and asphyxiation 187 The current situation 163 Vaccine development 163 Interferon beta-1b for multiple sclerosis 187 Nucleoside therapy 164 Topical tretinoin and birth defects 188 US FDA to levy fees on pharmaceutical companies 189 Reports on Individual Drugs Women in drug trials: change in US policy 189 Digoxin and heart failure: does it increment the response to ACE inhibitors 169 Essential Drugs Inhaled glucocorticoids: safety in children 170 WHO Model List: revised in November 1993 190 Neonatal streptococcal infections: hope for a preventive strategy 172 Topical estrogens and recurrent post­ Proposed International menopausal urinary tract infections 175 Nonproprietary Names: List 70 203 Coumarins: symptomatic relief of filarial lymphoedema 177 Influenza vaccine: further reassurance regarding adverse effects 178 General Information Assessing the efficiency and reliability of aerosol drug delivery systems 180 Patients who don't take their medicines 181 Second malignancies after treatment of childhood cancers 182 Vaccines: managing the cold chain 183 i WHO Drug Information Vol. 7, No. 4, 1993 General Policy Topics Gene therapy: proposals concerning gene therapy and somatic- cell therapy have been submitted to the United the regulatory challenge States Food and Drug Administration, which retains responsibility for assessing the quality, safety and Over the past decade a remarkable insight has efficacy of products under development (2). The been gained into physiological processes as they range of applications to which such products are operate at cellular level. This has emerged from a already directed is highly diverse. As well
Load more

Recommended publications
  • Is It Compatible with Breastfeeding?
    International Journal of Medical Informatics 141 (2020) 104199 Contents lists available at ScienceDirect International Journal of Medical Informatics journal homepage: www.elsevier.com/locate/ijmedinf Is it compatible with breastfeeding? www.e-lactancia.org: Analysis of visits, T user profile and most visited products José María Paricio-Talayeroa, Desirée Mena-Tudelab,*, Águeda Cervera-Gaschb, Víctor Manuel González-Chordáb, Yasmin Paricio-Burtina, Marta Sánchez-Palomaresa, Nerea Casas-Maesoa,c, Silvia Moyano-Pellicera, Konstantina Gianniotia,c, Alberto Hearta, Leonardo Landa-Riveraa a Association for the Promotion of and Scientific and Cultural Research into Breastfeeding (APILAM), Spain b Department of Nursing. UniversitatJaume I. Castellón de la Plana, Spain c International Board Certified Lactation Consultant (IBCLC), Spain ARTICLE INFO ABSTRACT Keywords: Introduction: One of the factors to influence abandoning breastfeeding is mothers’ use of medications. The www. Breast feeding e-lactancia.org website is a reliable source in Spanish and English for online free-access information about the Pharmaceutical preparations compatibility of medications with breastfeeding. The aim of this study was to analyse the search profiles, and Information storage and retrieval groups and products, searched the most on this website. Product labelling Materials and methods: A retrospective and descriptive study of the e-lactancia.org website during 2014–2018. Drug labelling Google Analytics was used for data collection. The following variables were analysed: number of users and Telemedicine queries; professional profile; country; language; users’ and groups’ access modes/devices; most searched pro- ducts. Results: We found 16,821.559 users and 63,783.866 pages. Of users, 62.7 % were “mother/father”, and 31.9 % were health professionals.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WHO Drug Information
    WHO DRUG INFORMATION VOLUME 8 - N U M B E R 3 1994 RECOMMENDED INN LIST 34 INTERNATIONAL NONPROPRIETARY N A M E S F O R P H A R M A C E U T I C A L SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 8, Number 3, 1994 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Regulatory Matters Ethics and drug promotion: the CIOMS Large-scale HIV vaccine trials deferred 152 consensus 123 Antidepressants and hyponatraemia 152 Azapropazone and photosensitivity 153 Personal Perspectives Blood: safeguards to prevent Revision of the IFPMA code of pharmaceutical transmission of pathogens 153 Bromocriptine: no longer recommended to marketing practices 125 suppress lactation 153 Counterfeit medicines: a growing concern 154 Update on AIDS Felbamate and aplastic anaemia 154 HIV vaccines: advances and setbacks 128 Neuroleptic sensitivity in dementia 155 Zidovudine: redressment of early expectations 130 Nonsteroidal anti-inflammatory drugs: Zidovudine: renewed encouragement 131 relative safety 155 China to work with the European Reports on Individual Drugs Pharmacopoeia Commission 156 Antiarrhythmic agents: more concerns over Move to ban distribution of drug samples 156 risks and benefits 134 Theophylline potentiated by fluvoxamine 156 Oral contraceptives: no apparent association Tiaprofenic acid and severe cystitis 156 with diabetic complications 135 Zidovudine approved to prevent HIV Oral contraceptive use and protection against transmission in pregnancy 157 ovarian cancer 136 Ethical criteria for medicinal drug promotion
    [Show full text]
  • CNS Drug Reviews Vol
    CNS Drug Reviews Vol. 10, No. 1, pp. 45–76 © 2004 Neva Press, Branford, Connecticut Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature Joris C. Verster and Edmund R. Volkerts Utrecht Institute for Pharmaceutical Sciences, Department of Psychopharmacology, University of Utrecht, Utrecht, The Netherlands Keywords: Alprazolam — Benzodiazepines — Anxiety — Depression — Panic — Sedation. ABSTRACT Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazo- lam has a fast onset of symptom relief (within the first week); it is unlikely to produce de- pendency or abuse. No tolerance to its therapeutic effect has been reported. At discontinu- ation of alprazolam treatment, withdrawal and rebound symptoms are common. Hence, alprazolam discontinuation must be tapered. An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antide- pressants (TCAs), such as imipramine. However, although alprazolam and imipramine are significantly more effective than placebo in the treatment of panic attacks, Selective Sero- tonin Reuptake Inhibitors (SSRIs) appear to be superior to either of the two drugs. Therefore, alprazolam is recommended as a second line treatment option, when SSRIs are not effective or well tolerated. In addition to its therapeutic effects, alprazolam produces adverse effects, such as drowsiness and sedation. Since alprazolam is widely used, many clinical studies investi- gated its cognitive and psychomotor effects. It is evident from these studies that alprazo- lam may impair performance in a variety of skills in healthy volunteers as well as in pa- tients.
    [Show full text]
  • Labelling Project 99/00
    PO Box 100 Woden ACT 2606 Australia Telephone: (02) 6232 8444 Facsimile: (02) 6232 8241 Labelling project 99/00 Effective by design A discussion paper on possible reforms to the regulation of the labelling of medicines in Australia April 2000 ii You are invited to comment All interested parties are invited to respond to this paper. Specific questions and recommendations are placed within the text as a guide for responses. However, while answers to these will be helpful to us, your responses do not have to be restricted by these. Please send submissions to: Labelling Project 99/00 Review of Drugs and Poisons Legislation Branch (MDP88) PO Box 100 WODEN ACT 2606 Submissions will normally be regarded as public documents. If you wish any material to remain confidential, please identify this material and provided the basis for its confidential nature. Because comments on the matter of moving warnings on medicine labels out of the Standard for the Uniform Scheduling of Drugs and Poisons is required to feed into the Review of Drugs, Poisons and Controlled Substances Legislation, but stakeholders may need more time to consider the other issues, it is necessary to split the comments deadline dates. Closing dates for submissions: Friday 26 May 2000 for comments on SUSDP warnings movement to therapeutic goods legislation Friday 23 June 2000 for comments on the paper as a whole i ii Contents You are invited to comment .................................................................. i Summary ....................................................................................
    [Show full text]
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Sandoz Closes in on US Filgrastim Biosimilar
    Gen 16-1-15 Pg.1_Gen 18/11/05 Pg. 1 13/01/2015 16:40 Page 1 16 January2015 COMPANY NEWS 2 Sandoz closes in on US Abdi Ibrahim teams with Algerian player 2 Kremers deal falters 3 after US FDAaction Tianyin teams up to tackle its troubles 4 filgrastim biosimilar nod Apotex and Panacea allyovertwo drugs 5 US business booms to aid Zydus Cadila 6 andoz has taken amajor step towards securing the first approvalthrough the US Strides starts work on Malaysian facility 7 Sbiosimilar pathway after an advisory panel to the US Food and Drug Administration Walgreens completes 8 (FDA) recommended the agency should approve the company’s EP2006 filgrastim Alliance Boots deal candidate with all the same indications as its reference product, Amgen’s Neupogen. “Weare pleased with the Oncologic Drugs Advisory Committee’s(ODAC’s)recommendation MARKET NEWS 9 to approve our biosimilarfilgrastim and we look forward to continuing to work with FDAas it completes its reviewof our filing,”said Sandoz’ Mark McCamish. If the agencyfollows Suspensions in EU followGVK review 9 the committee’snon-binding advice, Sandoz proposes to market biosimilarfilgrastim pre- Four firms shareinSouth African tender 11 filled syringes in the US under the brand name Zarxio. Abriefing documentfor the ODAC meeting on 7January stated that “considering the Te va takes top spot among AOKawards 12 totality of the evidence, the data submitted by the applicant showthat EP2006 is highly similar GPhA voices concern 13 to US-licensed Neupogen. The clinical data have shown that there are no clinically meaningful over TPP provisions differencesbetween EP2006 and US-licensed Neupogen, suggesting that EP2006 should receive Russia mayconsider compulsorylicensing 14 licensure for each of the five indications for which Neupogen is currently licensed”.
    [Show full text]